PBI12 Budget Impact Analysis of Baricitinib for the Management of Moderate-to-Severe Rheumatoid Arthritis in the Kingdom of Saudi Arabia

Journal article

Open access

Peer reviewed

H. Almodaimegh, A. Alrumaih, H.A.A. Alabdulkarim, M. Alsaqa'aby, A. Alturaiki, A. Erdogan, M. Alhowimel, A. Alhammad, R. El Ojeil and C. Biswas

Value in health, Vol.23, pp.S412-S412

12/2020

Files and links (1)

url

https://doi.org/10.1016/j.jval.2020.08.090View

Published (Version of record) Open

1 Record Views

Title: PBI12 Budget Impact Analysis of Baricitinib for the Management of Moderate-to-Severe Rheumatoid Arthritis in the Kingdom of Saudi Arabia
Creators - without role: H. Almodaimegh - King Saud bin Abdulaziz University for Health Sciences
A. Alrumaih - Ministry of Defense
H.A.A. Alabdulkarim - National Guard Health Affairs
M. Alsaqa'aby - King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
A. Alturaiki - National Guard Health Affairs
A. Erdogan - Eli Lilly and Company, Riyadh, Saudi Arabia
M. Alhowimel - Eli Lilly
A. Alhammad - Eli Lilly
R. El Ojeil - IQVIA
C. Biswas - IQVIA
Publication Details: Value in health, Vol.23, pp.S412-S412
Publisher: Elsevier Inc
Identifiers: 9920649208331
Academic Unit: King Abdulaziz University; King Saud Bin Abdulaziz University for Health Sciences
Language: English
Resource Type: Journal article